Directory
Regulatory Hub
Plain-language, primary-sourced explainers on the FDA rules governing compounded semaglutide in 2026.
Is Compounded Semaglutide FDA-Approved?
Open →FDA Semaglutide Compounding Update 2026
Open →Compounded GLP-1 Timeline
Open →Semaglutide Shortage Status
Open →503A vs 503B Pharmacies
Open →What the FDA Says
Open →Bottom Line
Regulatory status is changing in 2026 — always confirm against FDA primary sources before relying on any program.
Compounded semaglutide is not FDA-approved as a finished drug product. Compounded medications may be prescribed only when clinically appropriate and must be evaluated by a licensed prescriber. Branded medications such as Wegovy and Ozempic are FDA-approved products; compounded semaglutide is different and should not be described as FDA-approved, “generic Wegovy,” or “generic Ozempic.”